Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
age1 is a venture capital organization founded by Alex Colville and Laura Deming, based in the United States. The firm focuses on funding companies that aim to extend healthy lifespan through longevity research. It is well-capitalized to support its portfolio companies through various funding rounds.
age1 invests in early-stage companies, including angel, pre-seed, seed, and series A rounds, with check sizes ranging from $500,000 to $4 million. The firm specifically targets biotech and healthcare sectors, concentrating on aging and age-related diseases.
age1 has backed several notable companies in the longevity sector, including ALXO, which develops foundational checkpoint immunotherapies; DBTX, focused on regenerative and gene therapies for hearing and balance; MTCR, which addresses gastrointestinal and liver diseases; DTIL, known for novel gene editing technology; and UBX, which aims to slow or reverse diseases of aging.
Submit through their form at age1.com or email info@age1.com with your deck.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.